The MAPS Act (S. 1784) is a federal supply-chain and national security bill focused on essential medicines and the pharmaceutical ingredients used to make them. It directs the Secretary of Health and Human Services, working with other federal agencies, to update and maintain an Essential Medicines List that includes drugs and active pharmaceutical ingredients important for emergency response, high-priority health care needs, chronic disease treatment, and military readiness. The list must be updated at least every two years and published after each update.
The bill also requires a comprehensive risk assessment of the supply chains for those essential medicines. That assessment must identify key starting materials and excipients, dependence on high-risk foreign suppliers or foreign entities of concern, reliance on foreign manufacturing, domestic manufacturing capacity, cybersecurity and critical infrastructure risks, gaps in federal authority or process, and possible mitigation tools, including the Defense Production Act. HHS must report findings to Congress and the intelligence community, with a public version released later.
In addition, the bill creates a pharmaceutical supply-chain mapping effort within HHS to visualize supply chains from raw materials through finished dosage forms and distribution, using data analytics to identify vulnerabilities that could threaten national security. It requires HHS to coordinate information-sharing across federal agencies and to report annually on mapping progress, agency roles, data gaps, predictive modeling, and industry engagement. The bill also directs the Department of Defense to provide biannual reports listing drugs it purchases that contain Chinese-sourced ingredients or are finished in China.
The bill would amend federal practice primarily through reporting, coordination, and information-sharing requirements rather than direct regulation of manufacturers. It interacts with existing FDA authorities, drug shortage reporting rules, and national security frameworks, while clarifying that interagency information exchange for these purposes is not a violation of federal confidentiality law, subject to existing trade-secret protections. It also deems HHS’s participation in updating the essential medicines list to satisfy prior executive-order requirements.
Overall, the available context suggests the bill is likely to be broadly supported as a bipartisan effort to strengthen pharmaceutical resilience, reduce dependence on foreign supply chains, and improve preparedness for shortages and emergencies. No vote data or committee transcript was provided, so there is no recorded floor sentiment; however, the bipartisan sponsorship and national security framing indicate generally favorable sentiment. The main points of contention are likely to center on data privacy, protection of confidential commercial information, the burden on industry and agencies, and concerns about reliance on China and other foreign suppliers in the drug supply chain.
The bill would add new federal duties for HHS and the Department of Defense to maintain an essential medicines list, assess supply-chain risks, map pharmaceutical supply chains, and report regularly to Congress and the intelligence community. It would not directly change state law, but it would affect federal oversight of drug manufacturing, shortages, procurement, and national security planning, with downstream effects on manufacturers, distributors, and health systems that rely on essential medicines and active pharmaceutical ingredients.
The bill’s framing and bipartisan sponsorship suggest a generally positive, security-oriented sentiment around the measure. It is presented as a preparedness and resilience bill aimed at preventing shortages and reducing foreign dependence, which are typically noncontroversial goals. No committee transcript or vote record was provided, so there is no evidence of formal opposition or recorded debate, but the likely support would be tempered by concerns about confidentiality, cybersecurity, and the administrative burden of new reporting and mapping requirements.
The most likely areas of contention are the scope of federal data collection, the handling of confidential commercial information, and the extent to which the bill could expose proprietary supply-chain details. Industry stakeholders may be concerned about reporting burdens, disclosure of manufacturing locations and sourcing relationships, and the security of sensitive supply-chain data. Some policymakers may also question the practicality of mapping complex global pharmaceutical supply chains and whether the bill goes far enough to address domestic manufacturing capacity and dependence on foreign suppliers, especially China.